Clinical Trial

A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the clinical benefit of XY0206 therapy in participants with FLT3-ITD mutated AML who are refractory to or have relapsed after prior AML therapy as shown with overall survival (OS) compared to salvage chemotherapy. In addition, this study is also to investigate the efficacy of XY0206 as assessed by CR/CRh rate in these subjects。
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-05-17.
Trial Details
NCT Number NCT05876832
Lead Sponsor Shijiazhuang Yiling Pharmaceutical Co. Ltd
Conditions Acute Myeloid Leukemia With FLT3/ITD Mutation
Enrollment 312 participants
Start Date 2023-06-15
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2023-05-26